A Berkeley Lab spin-out, Newomics is creating blood-based assays for diabetes diagnosis and management, and for the monitoring of environmental toxins, among other health care applications. The core technology, a multi-nozzle emitter array (MEA) for mass spectrometry, was developed by Newomics founder and president Daojing Wang, a guest scientist in Biological Systems and Engineering (BSE), while he was in the Lab’s Life Sciences Division (now part of the Biosciences Area). Collaborators on the emitter technology included Pan Mao, formerly in Life Sciences, and Peidong Yang in the Materials Sciences Division. Read more in the Berkeley Lab News Center.
Was this page useful?